Puromycin Aminonucleoside: Precision Nephrotoxic Agent for Podocyte Injury Modeling

Executive Summary: Puromycin aminonucleoside (CAS 58-60-6) is the aminonucleoside moiety of puromycin and is widely used to induce nephrotic injury in experimental models (APExBIO). It provokes proteinuria and glomerular lesions that resemble focal segmental glomerulosclerosis (FSGS) in vivo. The compound disrupts podocyte morphology, notably reducing microvilli and foot processes in vitro. Uptake is enhanced in PMAT-expressing cells and is pH-dependent, with cytotoxicity measurable by IC₅₀ values in MDCK cell lines. Puromycin aminonucleoside is highly soluble in DMSO, ethanol, and water, supporting flexible experimental workflows (Bridgene 2023).

Biological Rationale

Nephrotic syndrome disrupts the glomerular filtration barrier, leading to proteinuria, hypoalbuminemia, and edema. Podocyte dysfunction is central to disease pathogenesis (Proteinabeads 2023). Puromycin aminonucleoside reliably induces podocyte injury and models FSGS pathology in rats. It is used to dissect molecular mechanisms underlying glomerular disease. The agent facilitates studies on proteinuria induction, renal lipid accumulation, and filtration barrier breakdown. APExBIO provides validated lots for research reproducibility. Compared to older nephrotoxins, puromycin aminonucleoside exhibits robust, predictable effects at defined doses, enabling translational nephrology research. This article clarifies its mechanistic details and workflow integration, extending the guidance in Yeast Extract 2022 by detailing recent cytotoxicity and uptake benchmarks.

Mechanism of Action of Puromycin Aminonucleoside

Puromycin aminonucleoside acts by disrupting the actin cytoskeleton and causing foot-process effacement in differentiated podocytes. It reduces cell surface microvilli and impairs slit diaphragm integrity. In vitro, exposure leads to cytoskeletal collapse within hours, followed by loss of filtration capacity (APExBIO). In vivo, single or repeated dosing (typically 100–150 mg/kg in rats) triggers heavy proteinuria and glomerular sclerotic changes. PMAT (plasma membrane monoamine transporter) facilitates compound uptake, with a fourfold higher rate at pH 6.6 versus pH 7.4 in transfected lines. The IC₅₀ for cytotoxicity in vector- and PMAT-transfected MDCK cells is 48.9 ± 2.8 μM and 122.1 ± 14.5 μM, respectively, measured over 24–48 hours. Lipid accumulation is frequently observed in glomerular mesangial cells post-treatment. The compound does not directly inhibit RNA or DNA synthesis at standard experimental concentrations. These effects collectively recapitulate human nephrotic syndrome features.

Evidence & Benchmarks

• Puromycin aminonucleoside induces proteinuria and glomerular lesions within 3–7 days in Sprague-Dawley rats at 100–150 mg/kg (https://www.apexbt.com/puromycin-aminonucleoside.html).
• In vitro, podocyte treatment with 50–150 μM for 24–72 hours leads to microvilli reduction and actin cytoskeleton disruption (https://bridgene.com/index.php?g=Wap&m=Article&a=detail&id=15424).
• PMAT-mediated uptake is pH-sensitive: uptake at pH 6.6 is ~4x higher versus pH 7.4 in PMAT-expressing MDCK cells (https://www.apexbt.com/puromycin-aminonucleoside.html).
• Cytotoxicity IC₅₀ values are 48.9 ± 2.8 μM (vector) and 122.1 ± 14.5 μM (PMAT-expressing) in MDCK cells after 24–48 h (https://proteinabeads.com/index.php?g=Wap&m=Article&a=detail&id=10901).
• Compound is soluble at ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, ≥29.5 mg/mL in water (with gentle warming) (https://www.apexbt.com/puromycin-aminonucleoside.html).
• Stock solutions remain stable for several months at <-20°C; working solutions should be used promptly to avoid degradation (https://www.apexbt.com/puromycin-aminonucleoside.html).

Applications, Limits & Misconceptions

Puromycin aminonucleoside is the preferred agent for rapidly modeling nephrotic syndrome, podocyte injury, and FSGS in rodents. It also supports cytotoxicity and transporter function assays in vitro. The A3740 kit from APExBIO provides high-purity, validated reagent for reproducible studies. This article extends the mechanistic coverage of Bridgene 2022 by detailing pH-dependent uptake and PMAT transporter benchmarks.

Common Pitfalls or Misconceptions

• It does not model all forms of human glomerular disease; effects are most representative of FSGS and minimal change disease.
• Chronic administration in non-rodent species can yield inconsistent results due to species-specific differences in transporter expression and pharmacokinetics.
• The compound's nephrotoxicity is not mediated by direct DNA or RNA synthesis inhibition at standard research concentrations.
• Solutions degraded at room temperature or after repeated freeze-thaw cycles lose potency and reliability.
• Results may vary if PMAT or related transporter expression is altered by genetic manipulation or prior pharmacological treatments.

Workflow Integration & Parameters

Puromycin aminonucleoside is supplied as a powder (SKU A3740) and is compatible with most aqueous and organic solvent workflows. For in vivo studies, dissolve in sterile saline or water at ≥29.5 mg/mL (with gentle warming) and administer intraperitoneally or intravenously at 100–150 mg/kg. For in vitro use, dissolve at ≥14.45 mg/mL in DMSO or ≥29.4 mg/mL in ethanol, dilute to final concentrations of 10–150 μM in cell culture media. Maintain stock solutions at <-20°C for up to several months. Prepare fresh working solutions to ensure activity. Shipping is conducted under blue ice for small molecule format or dry ice for nucleotide-modified products. APExBIO's validated supply chain supports rigorous nephrotic injury and podocyte cytotoxicity modeling (Proteinabeads 2023), building on recommendations from Bridgene 2023 by specifying stability and handling best practices.

Conclusion & Outlook

Puromycin aminonucleoside remains the reference nephrotoxic agent for modeling podocyte injury, proteinuria, and FSGS in preclinical research. Its well-characterized mechanism, cytotoxicity profile, and transporter-mediated uptake provide robust benchmarks for nephrology studies. When sourced from validated vendors such as APExBIO, it supports high-fidelity experimental design and translational research. Future work will integrate puromycin aminonucleoside models with single-cell and omics workflows to dissect podocyte biology and renal disease progression at unprecedented resolution.